Home » Health » Genexine publishes phase 2 interim result of cervical cancer treatment’lancet’

Genexine publishes phase 2 interim result of cervical cancer treatment’lancet’

[이데일리 왕해나 기자]Genexine’s human papillomavirus (HPV) DNA vaccine’GX-188E’ (NOV1702), which is being developed as a new cervical cancer drug, and’Kitruda’ (ingredient name pembrolizumab) of MSD in the United States, are being developed as a new drug for cervical cancer. It was announced on the 7th that it was published in the journal’Lancet Oncology’.

Key clinical results of GX-188E and Kitruda combination. (Table = Lancet Oncology)

GX-188E is an immunotherapy vaccine that induces T cell immune responses specific to HPV type 16 and 18.

The published results are an interim report of phase 2 clinical trials for patients with end-stage recurrent or progressive cervical cancer infected with HPV type 16 or 18.

In a combined clinical trial involving GX-188E and Kitruda in a total of 26 patients, 4 patients showed complete remission (CR) with all tumors completely disappeared. Seven patients showed partial remission (PR) in which the size of the cancer decreased by more than 30%, and the objective response rate (ORR) of the combined GX-188E and Kitruda group was 42.3%. In addition, in a single-administered clinical trial, Kitruda responded only to patients who were PD-L1 positive, but one of the patients who responded in this clinical combination group was PD-L1 negative.

The incidence of adverse reactions was also similar to that of Kitruda monotherapy. The company explained that it has confirmed the safety of the combination of a DNA vaccine and an anticancer drug.

Seong Young-cheol, CEO of Genexine, said, “We look forward to delivering hope to patients with end-stage cervical cancer by doing our best to commercialize the combination of GX-188E and Kitruda early.

– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.